Le Lézard
Classified in: Health, Science and technology
Subject: VET

Lovell and MedRhythms Partner to Provide Access to InTandemtm for Veterans and Military Personnel with a Walking Impairment Due to a Stroke


InTandem is an evidence-based gait rehabilitation device designed to be used by a stroke survivor in their home environment to improve walking and ambulation.

PORTLAND, Maine, Nov. 8, 2023 /PRNewswire/ -- Lovell Government Services and MedRhythms, Inc. announced their partnership establishing access to InTandem for Veterans and military personnel living with chronic stroke walking impairment. InTandem is a novel device that clinicians involved in stroke rehabilitation can prescribe to their patients to improve their walking and ambulation following a stroke.

Over 80,000 Veterans have experienced at least one stroke. Stroke is a leading cause of long-term disability including impairments to walking ability. Recent research shows the potential for continued recovery in the chronic phases of stroke. Interventions, such as InTandem, that can be prescribed for patients to use independently in their homes (including retirement homes and domiciliary care), are an effective answer to create access to this much-needed rehabilitation care.

Lovell Government Services will serve as InTandem's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, providing access to all government organizations and Federal healthcare systems, including the Veterans Health Administration (VHA), the Military Health System (MHS), and Indian Health Services (IHS). InTandem is listed on the Federal Supply Schedule (FSS) and GSA Advantage federal contracts. Listing products with Lovell streamlines the acquisition process and assists government agencies in meeting their SDVOSB procurement goals.

"We are a proud partner of Lovell and as such be able to serve those who served our country by providing access to InTandem," said Barbara Heikens, VP of Commercial at MedRhythms.

"MedRhythms' InTandem is a perfect fit for Federal Healthcare. It allows patients who have survived stroke to regain their quality of life, in a way that is engaging and enriching, all from the comfort of their home or domiciliary. Lovell is very honored to offer InTandem on our catalogs," Chris Lovell, USMC Major (Ret.), CEO, Lovell Government Services.

To learn more about InTandem visit: https://intandemrx.com

InTandem and MedRhythms at VA Small Business Industry Days
The MedRhythms team will be at the Louis Stokes Cleveland VA Medical Center on Thursday, November 9th, 2023 in Cleveland, OH. Visit the atrium to learn more about InTandem.

About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a two-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.

Learn more at www.lovellgov.com

About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of products across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. In 2020, the company's product for chronic stroke walking deficits received Breakthrough Device Designation, and in 2021 the company partnered with Universal Music Group and raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine.

For more information, visit www.medrhythms.com.

MedRhythms and InTandem are trademarks of MedRhythms, Inc.

Forward-Looking Statements
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.

SOURCE MedRhythms


These press releases may also interest you

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...

at 02:45
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024....

at 02:25
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies...

at 02:20
BioInvent International (STO:BINV)"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking...



News published on and distributed by: